Overview
- Inventia Healthcare initiated a voluntary recall on June 5 of two lots — RISA24001 (100-count) and RISB24002 (1,000-count) — that together total 11,460 bottles with an April 2027 expiration date.
- The FDA’s enforcement page shows the tablets failed dissolution testing, which means the pills may not dissolve as intended and could deliver less or inconsistent medication to patients.
- The recalled tablets were manufactured in India and distributed in the U.S. by Rising Pharma Holdings of East Brunswick, New Jersey, and the recall is ongoing while the FDA has not yet issued a separate press release.
- Patients taking 25 mg chlorthalidone should check their bottle’s NDC, lot number and expiration date and consult a pharmacist or clinician before stopping or changing treatment.
- Although the recall covers a limited number of bottles, the failure adds to recent dissolution-related quality concerns in the generic drug supply and could prompt wider testing, pharmacy recalls, or short-term availability effects.